Amgen Price Target Reduced at Piper Sandler but Long-Term Outlook Remains Positive - {财报副标题}

Live News

Amgen Price Target Reduced at Piper Sandler but Long-Term Outlook Remains Positive{随机描述}- Price target revision: Piper Sandler cut its target to $427 from $432, a modest reduction of about 1.2%, while maintaining an Overweight rating—suggesting the firm sees a favorable risk/reward profile at current levels. - Revenue upside potential: The firm believes that consensus estimates for 2026 and 2027 may be underestimated, with upside coming from rare disease drugs rather than legacy commercial products. - Rare disease momentum: Uplizna, a treatment for IgG4-related disease and other autoimmune conditions, is cited as a key driver. Strong uptake could push revenue above current Street expectations. - Tepezza growth catalyst: Recent Phase III results for Tepezza’s subcutaneous formulation were described as strong, positioning the drug as a potential long-term growth lever if approved for broader use. - Inclusion in “Dogs of the Dow” list: Amgen’s presence on such a list may appeal to income-oriented investors, as “Dogs of the Dow” strategies often focus on high-dividend-yield stocks with turnaround potential. Amgen Price Target Reduced at Piper Sandler but Long-Term Outlook Remains Positive{随机描述}{随机描述}Amgen Price Target Reduced at Piper Sandler but Long-Term Outlook Remains Positive{随机描述}

Key Highlights

Amgen Price Target Reduced at Piper Sandler but Long-Term Outlook Remains Positive{随机描述}On May 14, Piper Sandler reduced its price recommendation on Amgen Inc. (NASDAQ:AMGN) to $427 from $432, though it reiterated an Overweight rating on the stock. According to the firm, the outlook remains constructive from a broader business perspective, with analysts noting potential upside to consensus revenue estimates not only for 2026 but also for the 2027 period. The optimism, however, is less tied to Amgen’s core commercial portfolio and more anchored in continued momentum within the rare disease segment—especially Uplizna. Piper also highlighted Tepezza as a possible long-term growth catalyst, following strong Phase III results for its subcutaneous formulation. The report comes shortly after a separate note on May 7 from Freed, though details of that analysis were not fully disclosed in the source. Amgen was also recently featured in a list of the “10 Best ‘Dogs of the Dow’ Stocks to Buy for the Rest of 2026,” underscoring its income-focused appeal among large-cap pharmaceutical names. Amgen Price Target Reduced at Piper Sandler but Long-Term Outlook Remains Positive{随机描述}{随机描述}Amgen Price Target Reduced at Piper Sandler but Long-Term Outlook Remains Positive{随机描述}

Expert Insights

Amgen Price Target Reduced at Piper Sandler but Long-Term Outlook Remains Positive{随机描述}The price target reduction by Piper Sandler, while modest, may reflect near-term uncertainties around Amgen’s core commercial portfolio, including biosimilar competition and pricing pressures. However, the maintained Overweight rating signals that the firm believes these headwinds are offset by growth opportunities in rare diseases. The emphasis on Uplizna and Tepezza suggests Piper Sandler expects the company’s pipeline and recent clinical wins to support earnings acceleration beyond 2026. Investors should note that a price target cut does not necessarily indicate a bearish stance; rather, it may represent a recalibration of valuation assumptions. The inclusion in a “Dogs of the Dow” list could also attract attention from yield-focused strategies, but such lists are backward-looking and not guarantees of future performance. Overall, the analysis underscores the importance of monitoring clinical milestones and rare disease adoption—areas that may drive differentiation from large-cap peers. Any investment decision should consider broader market conditions, regulatory outcomes, and the company’s ability to sustain growth in its non-commercial segments. Amgen Price Target Reduced at Piper Sandler but Long-Term Outlook Remains Positive{随机描述}{随机描述}Amgen Price Target Reduced at Piper Sandler but Long-Term Outlook Remains Positive{随机描述}